New pill combo shows promise in shrinking breast tumors before surgery
NCT ID NCT07410559
First seen Feb 15, 2026 · Last updated Apr 28, 2026 · Updated 13 times
Summary
This study tests two drugs (imlunestrant and abemaciclib) given before surgery to shrink tumors in people with a common type of breast cancer (ER-positive, HER2-negative). About 189 women aged 18-75 will take these pills for a few weeks, and doctors will check how well the tumor responds using a marker called Ki67. The goal is to see if this combination can reduce or eliminate cancer before the operation, potentially leading to better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.